1) Recent studies have shown that some blood stored until the end of the storage period is not suitable for transfusion due to deterioration of blood cells, leading to side effects and even death. 2) The company Trustfusion has developed a non-invasive method and device for testing blood quality during storage that provides results in 1-2 minutes, much faster than competitors' tests. 3) Their device consists of two modules - one to establish blood cell flow and another to measure light transmission to determine blood quality. This allows for automated testing of blood inside storage bags.

1. Trustfusion
for english version see slide 16
ver. 17.09.2013

2. !"#$%&'(
2
)&*+(, "&-&./& # 0&"&%/1(.// 0"/./'(&2,3
.( #,.#1& ,"#4( 5"(.&./3. 6&7(1.#
0"#1&78..9& /,,%&7#1(./3 0#4(:(%/, +2#
+(,2; 4"#1/ 4 #4#.+(./< ,"#4( .&0"/=#7.(
7%3 /,0#%;:#1(./3, 2.4. 0#"232,3 >#"'&..9&
?%&'&.29. @2# 0"/1#7/2 4 "(:%/+.9'
0#$#+.9' ?>>&42(' 10%#2; 7# ,'&"2/.

3. !"/ 0&"&%/1(.// ?"/2"#A/2#1 , '&.;-/'
,"#4#' 5"(.&./3 ,'&"2.#,2; 1 1,5 "(:( ./C&.
3
Anemia and blood transfusion in critically ill patients / V. J, B. J, R. K, et al // JAMA. 2002.
Vol. 288, no. 12. P. 1499–1507.
Duration of red-cell storage and complications after cardiac surgery / C. G. Koch, L. Li, D. I.
Sessler et al. // New England Journal of Medicine. 2008. Vol. 358, no. 12. P. 1229–1239.

4. @4,0&"2.#& '.&./&
!"#$%&' ("#")*+&#,'-. "+/-0 '1 '12 3&+"4 "(5&4&#&'*6
71%&8+01 75"0* 9&/ 0875-+*6 3&271:
• :&#"0 ;.<. — :(1. #27. 0&"&%/1(./3 4"#1/ DEFG1 /'. 6.H. !/"#=#1(,
:(,%IC&..9* 1"(+ JK, %(I"&(2 0"&'// !"(1/2&%;,21( L#,419 1 #$%(,2/
'&7/A/.9, 4. '. .., 1"(+-2"(.,>I:/#%#= 19,-&* 4(2&=#"//
• =31&0 >.>. - (.&,2&:/#%#=-"&(./'(2#%#=, 2"(.,>I:/#%#= 6HH
.&*"#5/"I"=// /'. 6.6. FI"7&.4#
• ="'*4* <.?. - 1"(+-0,/5#.&1"#%#=, "(:"($#2+/4 '&7/A/.,4/5
0"/$#"#1, MMM "L("(>#."
• @&8+"(1#"0 >.;. - 7.'..., 0"#>&,,#", :(,%IC&..9* 1"(+ JK,
0"&0#7(1(2&%; '&7/A/.,4#=# >(4. JNO6, (.&,2&:/#%#=-"&(./'(2#%#=
DPED /'. 6.6. FI"7&.4#
4

5. J&-&./&
5
J&(%/:I<Q/* '&2#7 0"/$#" ,#,2#/2 /: 71I5
'#7I%&* — #7/. ,#:7(82 0#2#4 >#"'&..95
?%&'&.2#1, 0#,2#3..# /:'&.3<Q/*
.(0"(1%&./& 71/C&./3, ( 12#"#* /:'&"3&2
,1&2#0"#0I,4(./& 1 ?2/5 I,%#1/35 / 7&%(&2
191#79 # 4(+&,21& 4"#1/. )A&.("/*
1:(/'#7&*,21/3 1"(+( , 0"/$#"#': '&-#4
0#'&Q(&2,3 1 0"/$#", 4#2#"9* 10+"31+*%&87*
1,8 /:'&"3&2. R(=#"(&2,3 ,##21&2,21I<Q/*
/.7/4(2#" (:&%8.9* — 1,8 5#"#-#, 4"(,.9* —
4"#1; /,0#"+&.().

6. E#.4I"&.29
Blaze Medical
Devises
LightIntegra Trustfusion
Стерильность – + +
Себеcтоимость
теста
высокая высокая минимальная
Время на тест 20 мин 15 мин 1-2 мин
Универсаль-
ность
Эритроциты Тромбоциты
Эритроциты /
Тромбоциты
6
M$( 4#.4I"&.2( 0#4( .& 19-%/ .( "9.#4

7. F/:.&,-'#7&%;
L&7. I+"&C7&./&
Trustfusion
!"#$%&'(&)
*#'&(+,-&
$./!+.&
0"/$#"
30 .*!/'"#'
$I5=(%2&"/3
01"2"#)3(45
#36' ≈ 1700 .*!.
7

8. J9.#4
83."19"(/5 11 000 5 700 12 000
;"."%/,&(/5,
9+</=+9
7, 6 2%(. 15 2%(. 13 2%(.
>2-+#'? .4(-&,
2%(. $/=+9
7,6 22,5 19,5
;.+9&1/,
2%(. $ /=+9
0,76 2,25 1,95
8
* “J&,I",9 / 7&32&%;.#,2; I+"&C7&./* :7"(1##5"(.&./3”, #2+82 O&0("2('&.2( (.(%/:(, 0"#=.#:(, "(:1/2/3 :7"(1##5"(.&./3 /
'&7/A/.,4#* .(I4/ L/./,2&",21( :7"(1##5"(.&./3 JK
** NBCUS 2009 Report
*** The Collection, Testing and Use of Blood and Blood Components in Europe, EDQM 2008 report
* ** ***

9. K/.(.,9
9
-90
-60
-30
0
30
60
III 2013 III 2014 III 2015 III 2016 III 2017
'%.."I$.

10. !%(.9
!#,&1 6HJ MEJ
L(%(3
0("2/3
10

11. E#'(.7( — /.C&.&"9
S%/3 F(+/.(
F/#'&7/A/.,4(3
2&5./4(
T%8.( )#%#1;&1(
F/#'&7/A/.,4(3
2&5./4(
T%&4,(.7" L/5(*%#1
U&5.#%#=/+&,4#&
0"&70"/./'(2&%;,21#
/,,%&7#1(./3"(:"($#24( 0"/$#"(
11

12. E#'(.7(
6/4#%(* !(1%#1
L&7/A/.(
,13:; , 1"(+('/
O&./, EI:/.
U&5.#%#=/+&,4#&
0"&70"/./'(2&%;,21#
#$Q&& "I4#1#7,21#
12

13. E#'(.7(
6/4#%(* EI2I:#1
F/#>/:/4(
/,,%&7#1(./3
)0("2(4 EI'(.A&1
@4#.#'/4(
>/.(.,9
O(.//% !(1%&.4#
F/#2&5.#%#=/3
H)
13

14. E#'(.7(
T2(I%%(5(.#1 K. H.
6(I+.9*
"I4#1#7/2&%;
!/1#1("#1 H. M.
L&.2#"
14

15. Trustfusion Ltd.
@$&#/!+ <& ,(/2&(/"!
15

16. Problem
16
Nowadays the decision on transfusion is
taken on the basis of the storage period.
Recent studies have shown that some of the
blood to the end of the storage is not
suitable for use because blood cells
deteriorate. This leads to various side
effects, including death.

17. Mortality rate 1,5 times higher in transfusions
of erythrocyte units with higher storage time.
17
w transfusion
w/o transfusion
Mortalityrate,%
Days
Anemia and blood transfusion in critically ill patients / V. J, B. J, R. K, et al // JAMA. 2002.
Vol. 288, no. 12. P. 1499–1507.
Duration of red-cell storage and complications after cardiac surgery / C. G. Koch, L. Li, D. I.
Sessler et al. // New England Journal of Medicine. 2008. Vol. 358, no. 12. P. 1229–1239.

18. Expert opinions
We’ve got positive feedback on our method of our non-invasive (without
opening the bag) blood quality control method:
• Belov E. V. — chief of GKB G 1 transfusion department, merited physician of
RF, laureate of Moscow Government prize in medicine, M.D., highest grade
physician-transfusiologist
• Imaev A. A. - anaesthetist, transfusiologist of neurosurgery RI named after
N. N. Burdenko
• Ionidi V. U. - psychoneurologist, medical devices developer, "Marathon" LLC
• Shestopalov A. E. - Dr. Hab. Med., prof., merited physician of RF, teacher of
PFUR medical faculty, anaesthetist of Hospital named after N. N. Burdenko
18

19. Solution
19
The device, implementing the method consists of
two modules. One of them establishes a flow of
blood cells, constantly changing its direction, and
other determines blood quality on measurements of
the light transmission in these conditions.
Use scenario: the bag is placed in a device, device
automatically tests blood inside bag. Indicator
lights up (green — all OK, red — blood spoiled).

20. Competitors
Blaze Medical
Devises
LightIntegra Trustfusion
Sterility – + +
Test prime cost high high minimal
Test duration 20 min. 15 min. 1-2 min.
Universality Erythrocytes Thrombocytes
Erythrocytes &
Thrombocytes
20
Both of our competitors has not reached market yet.

21. Business model
Health care institution
Trustfusion
free device
installation
device
30 rub/test
accountant
Monthly invoice
≈ 1700 rub.
21

22. Market
Installation places 11 000 5 700 12 000
Transfusions,
dose/year
7,6 mln. 15 mln. 13 mln.
Market size,
mln. $/year
7,6 22,5 19,5
Our sales,
mln. $/year
0,76 2,25 1,95
22
* ** ***
* “Resources and activities of healthcare institutions” report by Ministry of Health of Russia
** NBCUS 2009 Report
*** The Collection, Testing and Use of Blood and Blood Components in Europe, EDQM 2008 report

23. Finances
23
-90
-60
-30
0
30
60
III 2013 III 2014 III 2015 III 2016 III 2017
mln.rub.

24. Plans
24
Market analysis
Patenting
Lab. prototype of device
Statement of work
Prototype development
Analyze methods development
Scientific marketing
Production prototype development
Certification
Clinical trials
Client development
Salesstart

25. Team — engineering
Yuliya Bachina
Biomedical
devices
Alena Solovyova
Biomedical
devices
Aleksandr Mikhailov
Technological
entrepreneurship
researchesdevice development
25

26. Team
Nikolay Pavlov
Medicine
physician contacts
Denis Kuzin
Technological
entrepreneurship
CEO
26

27. Team
Nikolay Kutuzov
Biophysics
research
Spartak Kumantsev
Economics
finances
Daniil Pavlenko
Biotechnology
IP
27

28. Team
Ataullakhanov F. I.
Scientific
leader
Pivovarov I. O.
Mentor
28

29. Transfusion becomes Trustfusion
with our device.
Trustfusion Ltd.
http://trustfusion.com
29